Eli Lilly

Eli Lilly is one of the big names in prescription medicines, especially in diabetes, oncology, immunology and newer weight-loss treatments, so it is followed closely by patients, doctors and investors alike. By our assessment, its strength is the depth of its drug pipeline and its ability to turn lab work into products that matter in real treatment plans. The downside is plain too: drugmakers live and die by patents, trial results and regulators, and that makes the business less steady than it can look from the outside. In practice, the company sits in the part of healthcare where the stakes are high and the scrutiny is constant, not in the quieter world of generic suppliers. It is a serious player rather than a broad consumer brand, and that makes it more relevant to people tracking therapies than to anyone looking for an everyday-name company.